159 related articles for article (PubMed ID: 21274943)
1. Synthesis and biological evaluation of prodrugs based on the natural antibiotic duocarmycin for use in ADEPT and PMT.
Tietze LF; Schmuck K; Schuster HJ; Müller M; Schuberth I
Chemistry; 2011 Feb; 17(6):1922-9. PubMed ID: 21274943
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological studies of different duocarmycin based glycosidic prodrugs for their use in the antibody-directed enzyme prodrug therapy.
Tietze LF; Schuster HJ; Krewer B; Schuberth I
J Med Chem; 2009 Jan; 52(2):537-43. PubMed ID: 19143570
[TBL] [Abstract][Full Text] [Related]
3. Asymmetric synthesis and biological evaluation of glycosidic prodrugs for a selective cancer therapy.
Tietze LF; von Hof JM; Krewer B; Müller M; Major F; Schuster HJ; Schuberth I; Alves F
ChemMedChem; 2008 Dec; 3(12):1946-55. PubMed ID: 19021160
[TBL] [Abstract][Full Text] [Related]
4. Duocarmycin-based prodrugs for cancer prodrug monotherapy.
Tietze LF; Schuster HJ; Schmuck K; Schuberth I; Alves F
Bioorg Med Chem; 2008 Jun; 16(12):6312-8. PubMed ID: 18524605
[TBL] [Abstract][Full Text] [Related]
5. Selective treatment of cancer: synthesis, biological evaluation and structural elucidation of novel analogues of the antibiotic CC-1065 and the duocarmycins.
Tietze LF; Major F; Schuberth I; Spiegl DA; Krewer B; Maksimenka K; Bringmann G; Magull J
Chemistry; 2007; 13(16):4396-409. PubMed ID: 17455190
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of novel pyrrolo[2,1-c][1,4]benzodiazepine prodrugs for use in antibody-directed enzyme prodrug therapy.
Masterson LA; Spanswick VJ; Hartley JA; Begent RH; Howard PW; Thurston DE
Bioorg Med Chem Lett; 2006 Jan; 16(2):252-6. PubMed ID: 16290933
[TBL] [Abstract][Full Text] [Related]
7. Photoactivatable prodrugs of highly potent duocarmycin analogues for a selective cancer therapy.
Tietze LF; Müller M; Duefert SC; Schmuck K; Schuberth I
Chemistry; 2013 Jan; 19(5):1726-31. PubMed ID: 23225610
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of the first spacer containing prodrug of a duocarmycin analogue and determination of its biological activity.
Schuster HJ; Krewer B; von Hof JM; Schmuck K; Schuberth I; Alves F; Tietze LF
Org Biomol Chem; 2010 Apr; 8(8):1833-42. PubMed ID: 20449487
[TBL] [Abstract][Full Text] [Related]
9. Selective cancer therapy by extracellular activation of a highly potent glycosidic duocarmycin analogue.
Chen KC; Schmuck K; Tietze LF; Roffler SR
Mol Pharm; 2013 May; 10(5):1773-82. PubMed ID: 23448264
[TBL] [Abstract][Full Text] [Related]
10. Antibody-directed enzyme prodrug therapy: a promising approach for a selective treatment of cancer based on prodrugs and monoclonal antibodies.
Tietze LF; Krewer B
Chem Biol Drug Des; 2009 Sep; 74(3):205-11. PubMed ID: 19660031
[TBL] [Abstract][Full Text] [Related]
11. New Taxol (paclitaxel) prodrugs designed for ADEPT and PMT strategies in cancer chemotherapy.
Alaoui AE; Saha N; Schmidt F; Monneret C; Florent JC
Bioorg Med Chem; 2006 Jul; 14(14):5012-9. PubMed ID: 16554162
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of water-soluble glucuronide derivatives of camptothecin for cancer prodrug monotherapy and antibody-directed enzyme prodrug therapy (ADEPT).
Leu YL; Roffler SR; Chern JW
J Med Chem; 1999 Sep; 42(18):3623-8. PubMed ID: 10479293
[TBL] [Abstract][Full Text] [Related]
13. A new paclitaxel prodrug for use in ADEPT strategy.
Bouvier E; Thirot S; Schmidt F; Monneret C
Org Biomol Chem; 2003 Oct; 1(19):3343-52. PubMed ID: 14584798
[TBL] [Abstract][Full Text] [Related]
14. Novel analogues of CC-1065 and the duocarmycins for the use in targeted tumour therapies.
Tietze LF; Krewer B
Anticancer Agents Med Chem; 2009 Mar; 9(3):304-25. PubMed ID: 19275523
[TBL] [Abstract][Full Text] [Related]
15. Antitumor agents: development of highly potent glycosidic duocarmycin analogues for selective cancer therapy.
Tietze LF; Major F; Schuberth I
Angew Chem Int Ed Engl; 2006 Oct; 45(39):6574-7. PubMed ID: 16960905
[No Abstract] [Full Text] [Related]
16. Synthesis and biological evaluation of antibody conjugates of phosphate prodrugs of cytotoxic DNA alkylators for the targeted treatment of cancer.
Zhao RY; Erickson HK; Leece BA; Reid EE; Goldmacher VS; Lambert JM; Chari RV
J Med Chem; 2012 Jan; 55(2):766-82. PubMed ID: 22148292
[TBL] [Abstract][Full Text] [Related]
17. Prodrugs for targeted tumor therapies: recent developments in ADEPT, GDEPT and PMT.
Tietze LF; Schmuck K
Curr Pharm Des; 2011; 17(32):3527-47. PubMed ID: 22074425
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationships for 4-nitrobenzyl carbamates of 5-aminobenz[e]indoline minor groove alkylating agents as prodrugs for GDEPT in conjunction with E. coli nitroreductase.
Hay MP; Atwell GJ; Wilson WR; Pullen SM; Denny WA
J Med Chem; 2003 Jun; 46(12):2456-66. PubMed ID: 12773049
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and antitumor activity evaluations of albumin-binding prodrugs of CC-1065 analog.
Wang Y; Jiang J; Jiang X; Cai S; Han H; Li L; Tian Z; Jiang W; Zhang Z; Xiao Y; Wright SC; Larrick JW
Bioorg Med Chem; 2008 Jul; 16(13):6552-9. PubMed ID: 18508273
[TBL] [Abstract][Full Text] [Related]
20. Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy.
Florent JC; Dong X; Gaudel G; Mitaku S; Monneret C; Gesson JP; Jacquesy JC; Mondon M; Renoux B; Andrianomenjanahary S; Michel S; Koch M; Tillequin F; Gerken M; Czech J; Straub R; Bosslet K
J Med Chem; 1998 Sep; 41(19):3572-81. PubMed ID: 9733483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]